e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Refining definitions of time to clinical worsening in connective tissue disease-associated pulmonary arterial hypertension
R. Zamanian, L. Chung, L. Parsons, D. Miller, Z. Safdar, M. McGoon, P. Hassoun, M. Nicolls, A. Frost (San Francisco, Houston, Rochester, Baltimore, United States Of America)
Source:
Annual Congress 2010 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
E-Communication Session
Number:
3522
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Zamanian, L. Chung, L. Parsons, D. Miller, Z. Safdar, M. McGoon, P. Hassoun, M. Nicolls, A. Frost (San Francisco, Houston, Rochester, Baltimore, United States Of America). Refining definitions of time to clinical worsening in connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2010; 36: Suppl. 54, 3522
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Early risk prediction in idiopathic
versus
connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
Source: ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020
Year: 2021
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Source: Eur Respir J, 50 (2) 1602493; 10.1183/13993003.02493-2016
Year: 2017
Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment
Source: Eur Respir Rev 2014; 23: 505-509
Year: 2014
Pulmonary arterial hypertension associated with connective tissue disease: an integrated approach
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Pulmonary arterial hypertension in connective tissue diseases
Source: Eur Respir Mon 2012; 57: 42-57
Year: 2012
Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
Source: Annual Congress 2012 - Limiting factors in exercise
Year: 2012
Veno-occlussive lesions and inflammation in pulmonary arterial hypertension associated with connective tissue diseases
Source: Annual Congress 2007 - Pulmonary hypertension in the clinic
Year: 2007
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Clinical and polysomnographic findings in patients with connective tissue disease and pulmonary hypertension
Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep
Year: 2008
The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients
Source: Eur Respir J 2014; 44: 963-972
Year: 2014
Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy
Source: Annual Congress 2013 –Clinical exercise physiology
Year: 2013
Acute effects of oxygen on pulmonary hemodynamic can help in differentiation of pulmonary hypertension at patients with connective tissue diseases
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015
First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
Year: 2018
Inflammatory pathways leading to pulmonary arterial hypertension in connective tissue diseases
Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases
Year: 2008
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension
Source: Eur Respir J, 52 (4) 1800678; 10.1183/13993003.00678-2018
Year: 2018
Identifying early pulmonary arterial hypertension in patients with systemic sclerosis
Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018
Year: 2018
Autoantibodies are frequently found in arterial and chronic thrombotic pulmonary hypertension not associated to connective tissue diseases
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help?
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept